Cargando…

Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia

Introduction: Screening for synthetic lethality markers has demonstrated that the inhibition of the cell cycle checkpoint kinases WEE1 together with CHK1 drastically affects stability of the cell cycle and induces cell death in rapidly proliferating cells. Exploiting this finding for a possible ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghelli Luserna Di Rorà, Andrea, Bocconcelli, Matteo, Ferrari, Anna, Terragna, Carolina, Bruno, Samantha, Imbrogno, Enrica, Beeharry, Neil, Robustelli, Valentina, Ghetti, Martina, Napolitano, Roberta, Chirumbolo, Gabriella, Marconi, Giovanni, Papayannidis, Cristina, Paolini, Stefania, Sartor, Chiara, Simonetti, Giorgia, Yen, Timothy J., Martinelli, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895917/ https://www.ncbi.nlm.nih.gov/pubmed/31717700 http://dx.doi.org/10.3390/cancers11111654

Ejemplares similares

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2018)

Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells
por: Ghelli Luserna Di Rorà, Andrea, et al.
Publicado: (2021)

A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2020)

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
por: Padella, Antonella, et al.
Publicado: (2022)

The balance between mitotic death and mitotic slippage in acute leukemia: a new therapeutic window?
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2019)

Targeting Proliferation Signals and the Cell Cycle Machinery in Acute Leukemias: Novel Molecules on the Horizon
por: Ghelli Luserna di Rorà, Andrea, et al.
Publicado: (2023)

CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies
por: Bruno, Samantha, et al.
Publicado: (2022)

Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions
por: Beeharry, Neil, et al.
Publicado: (2015)

Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2019)

Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway
por: Padella, Antonella, et al.
Publicado: (2021)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021)

The cell cycle checkpoint inhibitors in the treatment of leukemias
por: Ghelli Luserna di Rora’, A., et al.
Publicado: (2017)

Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma
por: Derenzini, Enrico, et al.
Publicado: (2015)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
por: Giudice, Valentina, et al.
Publicado: (2020)

Synthesis of Novel Tryptamine Derivatives and Their Biological Activity as Antitumor Agents
por: Simonetti, Giorgia, et al.
Publicado: (2021)

Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations
por: Ferrari, Anna, et al.
Publicado: (2023)

Immunosuppressive Treg cells acquire the phenotype of effector-T cells in chronic lymphocytic leukemia patients
por: De Matteis, Serena, et al.
Publicado: (2018)

Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia
por: Padella, Antonella, et al.
Publicado: (2019)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
por: Trino, Stefania, et al.
Publicado: (2016)

Wee1 and Chk1 – crosstalk between key players in replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia
por: Iacobucci, Ilaria, et al.
Publicado: (2015)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
por: Bertamini, Luca, et al.
Publicado: (2018)

Chromothripsis in Acute Myeloid Leukemia: biological features and impact on survival
por: Fontana, Maria Chiara, et al.
Publicado: (2017)

Chromothripsis in acute myeloid leukemia: biological features and impact on survival
por: Fontana, Maria Chiara, et al.
Publicado: (2018)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

Chk1 and Wee1 kinases coordinate DNA replication, chromosome condensation, and anaphase entry
por: Fasulo, Barbara, et al.
Publicado: (2012)

Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells
por: Mak, Joyce P.Y., et al.
Publicado: (2015)

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations
por: Simonetti, Giorgia, et al.
Publicado: (2021)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer
por: Wang, Qiming, et al.
Publicado: (2023)

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
por: Guertin, Amy D, et al.
Publicado: (2012)

Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis
por: Mak, Joyce P.Y., et al.
Publicado: (2014)

Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation
por: Zhao, Xiaoliang, et al.
Publicado: (2021)

Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients
por: Zuffa, Elisa, et al.
Publicado: (2015)

Acute Myeloid Leukemia Mutations: Therapeutic Implications
por: Papayannidis, Cristina, et al.
Publicado: (2019)

Combined Oral Fentanyl Citrate and Midazolam as Premedication for Bone Marrow Aspiration and Biopsy in Patients with Hematological Malignancies: A Randomized, Controlled and Patient-Blinded Clinical Trial
por: Cerchione, Claudio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_30ta3r61grh07r0sa4imvljfh7